{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:53:46Z","timestamp":1790967226007,"version":"4.1.0"},"reference-count":298,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["1-19-ACE-31"],"award-info":[{"award-number":["1-19-ACE-31"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000963","name":"American Diabetes Association Research Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022690","name":"Breakthrough T1D","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["2102-04998"],"award-info":[{"award-number":["2102-04998"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jconrel.2026.114705","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:53:05Z","timestamp":1770479585000},"page":"114705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Molecular engineering of designer diabetes therapeutics"],"prefix":"10.1016","volume":"392","author":[{"given":"Emily L.","family":"DeWolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114705_bb0005","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-021-01418-2","article-title":"100 years of insulin: celebrating the past, present and future of diabetes therapy","volume":"27","author":"Sims","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.114705_bb0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/db16-0806","article-title":"Differentiation of diabetes by pathophysiology, natural history, and prognosis","volume":"66","author":"Skyler","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb0020","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.autrev.2008.04.008","article-title":"Autoimmune mechanisms in type 1 diabetes","volume":"7","author":"Knip","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb0025","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes","volume":"389","author":"Chatterjee","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.114705_bb0030","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1210\/endrev\/bnaa015","article-title":"The evolution of insulin and how it informs therapy and treatment choices","volume":"41","author":"Hirsch","year":"2020","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrd.2015.36","article-title":"Pursuit of a perfect insulin","volume":"15","author":"Zaykov","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114705_bb0040","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.tips.2021.05.005","article-title":"Commemorating insulin\u2019s centennial: engineering insulin pharmacology towards physiology","volume":"42","author":"Kurtzhals","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0045","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb0055","first-page":"1","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/dom.13941","article-title":"Treatment and prevention of severe hypoglycaemia in people with diabetes: current and new formulations of glucagon","volume":"22","author":"Thieu","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2016.6","article-title":"Pancreatic regulation of glucose homeostasis","volume":"48","author":"R\u00f6der","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.114705_bb0070","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2337\/dbi22-0004","article-title":"The liver-\u03b1-cell axis in health and in disease","volume":"71","author":"Richter","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb0075","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb0080","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","article-title":"Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes","volume":"48","author":"Chapman","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2026.114705_bb0085","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmet.2021.03.020","article-title":"The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia","volume":"33","author":"Sylow","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb0090","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.2337\/db15-0629","article-title":"The brain-to-pancreatic islet neuronal map reveals differential glucose regulation from distinct hypothalamic regions","volume":"65","author":"Rosario","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb0095","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1152\/physrev.00025.2022","article-title":"The elusive cephalic phase insulin response: triggers, mechanisms, and functions","volume":"103","author":"Langhans","year":"2023","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb0100","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/jne.12285","article-title":"Pro-opiomelanocortin (POMC) neurones, POMC-derived peptides, melanocortin receptors and obesity: how understanding of this system has changed over the last decade","volume":"27","author":"Mountjoy","year":"2015","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0105","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.5114\/aoms.2015.56342","article-title":"Brain-derived neurotrophic factor and its clinical implications","volume":"11","author":"Bathina","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0110","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2337\/dc09-1499","article-title":"Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits","volume":"33","author":"Drucker","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2026.114705_bb0115","doi-asserted-by":"crossref","first-page":"FDD75","DOI":"10.4155\/fdd-2022-0005","article-title":"Overcoming the shortcomings of peptide-based therapeutics","volume":"4","author":"Lamers","year":"2022","journal-title":"Fut. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114705_bb0120","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrd1695","article-title":"Protein drug stability: a formulation challenge","volume":"4","author":"Frokjaer","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114705_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.563030","article-title":"D- and unnatural amino acid substituted antimicrobial peptides with improved proteolytic resistance and their proteolytic degradation characteristics","volume":"11","author":"Lu","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0130","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1021\/acs.jmedchem.9b01493","article-title":"Structural refinement of glucagon for therapeutic use","volume":"63","author":"Chabenne","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0135","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1177\/193229681000400605","article-title":"Optimization of the native glucagon sequence for medicinal purposes","volume":"4","author":"Chabenne","year":"2010","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0140","doi-asserted-by":"crossref","first-page":"12978","DOI":"10.1074\/jbc.272.20.12978","article-title":"Alanine scanning mutagenesis of insulin*","volume":"272","author":"Kristensen","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.molmet.2014.01.006","article-title":"A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia","volume":"3","author":"Chabenne","year":"2014","journal-title":"Mol. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb0150","first-page":"952","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo","volume":"80","author":"Deacon","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0160","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s001250050903","article-title":"Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity","volume":"41","author":"Deacon","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2026.114705_bb0165","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0170","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1021\/acsptsci.2c00174","article-title":"Amyloid fibrillation of insulin: amelioration strategies and implications for translation","volume":"5","author":"Fagihi","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0175","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41594-019-0238-6","article-title":"The peptide hormone glucagon forms amyloid fibrils with two coexisting \u03b2-strand conformations","volume":"26","author":"Gelenter","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0180","doi-asserted-by":"crossref","DOI":"10.1098\/rsfs.2017.0030","article-title":"Factors affecting the physical stability (aggregation) of peptide therapeutics","volume":"7","author":"Zapadka","year":"2017","journal-title":"Interface Focus"},{"key":"10.1016\/j.jconrel.2026.114705_bb0185","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1177\/193229681000400609","article-title":"The nature of amyloid-like glucagon fibrils","volume":"4","author":"Pedersen","year":"2010","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0190","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1021\/acs.biochem.1c00214","article-title":"Structurally based design of glucagon mutants that inhibit fibril formation","volume":"60","author":"Gelenter","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2026.114705_bb0195","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/acs.bioconjchem.1c00419","article-title":"Chemical synthesis and characterization of a nonfibrillating glycoglucagon","volume":"32","author":"Liu","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0200","doi-asserted-by":"crossref","first-page":"14503","DOI":"10.1021\/bi061228n","article-title":"N- and C-terminal hydrophobic patches are involved in fibrillation of glucagon","volume":"45","author":"Pedersen","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2026.114705_bb0205","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1021\/acsbiomaterials.1c00031","article-title":"A light activated glucagon trimer with resistance to fibrillation","volume":"7","author":"Chintala","year":"2021","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2026.114705_bb0210","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1021\/jm990559d","article-title":"Design and synthesis of conformationally constrained glucagon analogues","volume":"43","author":"Trivedi","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0215","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00228-021-03183-0","article-title":"Dasiglucagon: an effective medicine for severe hypoglycemia","volume":"77","author":"Xu","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0220","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/dc17-1402","article-title":"Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog","volume":"41","author":"H\u00f6velmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2026.114705_bb0225","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1016\/j.tet.2006.04.036","article-title":"\u03b1-Aminoisobutyric acid modified protected analogues of \u03b2-amyloid residue 17\u201320: a change from sheet to helix","volume":"62","author":"Haldar","year":"2006","journal-title":"Tetrahedron"},{"key":"10.1016\/j.jconrel.2026.114705_bb0230","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1002\/ange.200353565","article-title":"Inhibition of amyloid fibril formation by peptide analogues modified with \u03b1-aminoisobutyric acid","volume":"116","author":"Gilead","year":"2004","journal-title":"Angew. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0235","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.biocel.2005.12.009","article-title":"Role of islet amyloid in type 2 diabetes mellitus","volume":"38","author":"H\u00f6ppener","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2022.140866","article-title":"Understanding the mechanism of amylin aggregation: from identifying crucial segments to tracing dominant sequential events to modeling potential aggregation suppressors","volume":"1871","author":"Ghosh","year":"2023","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"key":"10.1016\/j.jconrel.2026.114705_bb0245","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/1874104501105010078","article-title":"Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function","volume":"5","author":"Adeghate","year":"2011","journal-title":"Open Med. Chem. J."},{"key":"10.1016\/j.jconrel.2026.114705_bb0250","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2798269","article-title":"Islet amyloid polypeptide: structure, function, and pathophysiology","volume":"2016","author":"Akter","year":"2016","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.jconrel.2026.114705_bb0255","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jmb.2005.09.100","article-title":"The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting","volume":"355","author":"Pedersen","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0260","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1002\/anie.201916257","article-title":"Multicomponent peptide stapling as a diversity-driven tool for the development of inhibitors of protein\u2013protein interactions","volume":"59","author":"Ricardo","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2026.114705_bb0265","doi-asserted-by":"crossref","first-page":"9836","DOI":"10.1021\/acs.chemrev.8b00744","article-title":"Multicomponent reaction toolbox for peptide macrocyclization and stapling","volume":"119","author":"Reguera","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb0270","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1039\/C4SC00045E","article-title":"Functionalised staple linkages for modulating the cellular activity of stapled peptides","volume":"5","author":"Lau","year":"2014","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0275","doi-asserted-by":"crossref","first-page":"14093","DOI":"10.1073\/pnas.1002713107","article-title":"Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic","volume":"107","author":"Bird","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0280","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1021\/jm4011675","article-title":"Hydrocarbon-stapled peptides: principles, practice, and progress","volume":"57","author":"Walensky","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0285","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/cbic.201700352","article-title":"Effect of stapling architecture on physiochemical properties and cell permeability of stapled \u03b1-helical peptides: a comparative study","volume":"18","author":"Tian","year":"2017","journal-title":"Chembiochemistry"},{"key":"10.1016\/j.jconrel.2026.114705_bb0290","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1021\/ja000563a","article-title":"An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides","volume":"122","author":"Schafmeister","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114705_bb0295","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1002\/anie.200900942","article-title":"Bioorthogonal chemistry: fishing for selectivity in a sea of functionality","volume":"48","author":"Sletten","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2026.114705_bb0300","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1021\/jm100602m","article-title":"Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges","volume":"53","author":"Murage","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0305","doi-asserted-by":"crossref","first-page":"17239","DOI":"10.1038\/s41598-017-16876-3","article-title":"Insulin in motion: the A6-A11 disulfide bond allosterically modulates structural transitions required for insulin activity","volume":"7","author":"van Lierop","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114705_bb0310","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1016-8478(23)13808-8","article-title":"Role of disulfide bonds in the structure and activity of human insulin","volume":"16","author":"Chang","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jconrel.2026.114705_bb0315","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1111\/febs.14849","article-title":"Beyond amino acid sequence: disulfide bonds and the origins of the extreme amyloidogenic properties of insulin\u2019s H-fragment","volume":"286","author":"Dec","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.jconrel.2026.114705_bb0320","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1038\/s41467-024-50477-9","article-title":"Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec","volume":"15","author":"Hub\u00e1lek","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114705_bb0325","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/pro.2211","article-title":"Insulin analog with additional disulfide bond has increased stability and preserved activity","volume":"22","author":"Vinther","year":"2013","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0330","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1039\/C9SC04555D","article-title":"Novel four-disulfide insulin analog with high aggregation stability and potency","volume":"11","author":"Xiong","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0335","doi-asserted-by":"crossref","first-page":"11437","DOI":"10.1021\/acs.jmedchem.9b01589","article-title":"Synthesis and characterization of an A6-A11 methylene thioacetal human insulin analogue with enhanced stability","volume":"62","author":"Zheng","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.650025","article-title":"Chemical glycosylation and its application to glucose homeostasis-regulating peptides","volume":"9","author":"Chandrashekar","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0345","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1073\/pnas.0801340105","article-title":"Effect of glycosylation on protein folding: a close look at thermodynamic stabilization","volume":"105","author":"Shental-Bechor","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0350","first-page":"1","article-title":"Chemical synthesis unveils extraordinary enhancement of glucagon-like peptide-1 stability by natural glycosylation","author":"Li","year":"2025","journal-title":"CCS Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0355","doi-asserted-by":"crossref","first-page":"17350","DOI":"10.1021\/jacs.5c03757","article-title":"Total chemical synthesis of glucagon Glycoforms reveals the remarkable influence of natural glycosylation","volume":"147","author":"Li","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114705_bb0360","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.xphs.2018.11.029","article-title":"The mechanistic impact of N-glycosylation on stability, pharmacokinetics, and immunogenicity of therapeutic proteins","volume":"108","author":"Zhou","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0365","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jps.2600840108","article-title":"Physical stabilization of insulin by glycosylation","volume":"84","author":"Baudys","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0370","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0169-409X(98)00078-7","article-title":"Site-specific insulin conjugates with enhanced stability and extended action profile","volume":"35","author":"Uchio","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb0375","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1021\/acs.accounts.4c00500","article-title":"Insulin stabilization designs for enhanced therapeutic efficacy and accessibility","volume":"57","author":"Zhang","year":"2024","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2026.114705_bb0380","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/bip.22030","article-title":"N-glycosylation of enhanced aromatic sequons to increase glycoprotein stability","volume":"98","author":"Price","year":"2012","journal-title":"Biopolymers"},{"key":"10.1016\/j.jconrel.2026.114705_bb0385","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1021\/acschembio.7b00794","article-title":"Chemically precise glycoengineering improves human insulin","volume":"13","author":"Guan","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0390","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/bph.13496","article-title":"Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development","volume":"173","author":"Bower","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0395","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1021\/acs.bioconjchem.3c00120","article-title":"Glycosylation improves the proteolytic stability of exenatide","volume":"34","author":"Chandrashekar","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0400","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1021\/ja900261g","article-title":"Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity","volume":"131","author":"Ueda","year":"2009","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114705_bb0405","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.carres.2017.11.007","article-title":"Chemo-enzymatic synthesis of the glucagon containing N-linked oligosaccharide and its characterization","volume":"455","author":"Higashiyama","year":"2018","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.jconrel.2026.114705_bb0410","doi-asserted-by":"crossref","first-page":"15084","DOI":"10.1002\/chem.201303303","article-title":"Glycosylation of pramlintide: synthetic glycopeptides that display in vitro and in vivo activities as amylin receptor agonists","volume":"19","author":"Tomabechi","year":"2013","journal-title":"Chemistry"},{"key":"10.1016\/j.jconrel.2026.114705_bb0415","doi-asserted-by":"crossref","first-page":"8142","DOI":"10.1039\/C4OB01208A","article-title":"Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure-activity relationships for amylin receptor agonism","volume":"12","author":"Kowalczyk","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0420","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.31635\/ccschem.021.202101115","article-title":"Protection-free site-directed peptide or protein S -glycosylation and its application in the glycosylation of glucagon-like peptide 1","volume":"4","author":"Li","year":"2022","journal-title":"CCS Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0425","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1021\/acs.jmedchem.4c00093","article-title":"Engineering of a biologically active glycosylated glucagon-like peptide-1 analogue","volume":"67","author":"Chandrashekar","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0430","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/07388551.2013.793649","article-title":"Glycosylation: impact, control and improvement during therapeutic protein production","volume":"34","author":"Costa","year":"2014","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0435","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.copbio.2006.06.010","article-title":"Challenges in therapeutic glycoprotein production","volume":"17","author":"Sethuraman","year":"2006","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0440","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.drudis.2016.01.006","article-title":"Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs","volume":"21","author":"Zhang","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.114705_bb0445","doi-asserted-by":"crossref","first-page":"34452","DOI":"10.1021\/jacs.4c11091","article-title":"Site-specific glyco-tagging of native proteins for the development of biologicals","volume":"146","author":"Gimeno","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114705_bb0450","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114705_bb0455","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/10837450.2019.1621896","article-title":"Physico-chemical stability of co-formulation of PEGylated human amylin with insulin","volume":"24","author":"Sin\u00e9sia","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0460","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00125-006-0234-3","article-title":"PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db\/db mice","volume":"49","author":"Lee","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2026.114705_bb0465","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1016\/j.bmcl.2005.06.002","article-title":"Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide","volume":"15","author":"Kieffer","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2026.114705_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2022.170749","article-title":"GLP-1 and GIP receptor signaling in beta cells - a review of receptor interactions and co-stimulation","volume":"151","author":"Mayendraraj","year":"2022","journal-title":"Peptides"},{"key":"10.1016\/j.jconrel.2026.114705_bb0475","article-title":"Stable monomeric insulin formulations enabled by supramolecular PEGylation of insulin analogues","volume":"3","author":"Maikawa","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb0480","doi-asserted-by":"crossref","first-page":"14189","DOI":"10.1073\/pnas.1616639113","article-title":"Supramolecular PEGylation of biopharmaceuticals","volume":"113","author":"Webber","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.114705_bb0485","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2147\/IJGM.S26889","article-title":"Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus","volume":"4","author":"Morello","year":"2011","journal-title":"IJGM"},{"key":"10.1016\/j.jconrel.2026.114705_bb0490","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199707173370307","article-title":"Insulin lispro","volume":"337","author":"Holleman","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114705_bb0495","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0140-6736(00)02546-0","article-title":"Insulin glargine","volume":"356","author":"Bolli","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.114705_bb0500","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1021\/acs.jmedchem.1c00257","article-title":"Molecular engineering of insulin Icodec, the first acylated insulin analog for once-weekly administration in humans","volume":"64","author":"Kjeldsen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb0505","doi-asserted-by":"crossref","DOI":"10.2337\/db20-237-OR","article-title":"237-OR: insulin icodec: an insulin analog suited for once-weekly dosing in type 2 diabetes","volume":"69","author":"H\u00f6velmann","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb0510","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.2023.11313","article-title":"Once-weekly insulin Icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial","volume":"330","author":"Lingvay","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2026.114705_bb0515","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.12782","article-title":"Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes","volume":"19","author":"Heise","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb0520","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1463-1326.2012.01580.x","article-title":"The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences","volume":"14","author":"Home","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb0525","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/nbt1340","article-title":"Renal clearance of nanoparticles","volume":"25","author":"Choi","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0530","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nnano.2017.170","article-title":"Glomerular barrier behaves as an atomically precise bandpass filter in a sub-nanometre regime","volume":"12","author":"Du","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0535","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.2337\/db15-1373","article-title":"Hepatic and extrahepatic insulin clearance are differentially regulated: results from a novel model-based analysis of intravenous glucose tolerance data","volume":"65","author":"Polidori","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb0540","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2337\/diacare.22.9.1501","article-title":"Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects","volume":"22","author":"Mudaliar","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2026.114705_bb0545","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-2005-865806","article-title":"Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects","volume":"113","author":"Becker","year":"2005","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb0550","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0149-2918(03)80156-X","article-title":"Insulin glargine: a systematic review of a long-acting insulin analogue","volume":"25","author":"Wang","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb0555","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1185\/030079902125001416","article-title":"Biotransformation of insulin glargine after subcutaneous injection in healthy subjects","volume":"19","author":"Kuerzel","year":"2003","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jconrel.2026.114705_bb0560","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6726","article-title":"Engineering biopharmaceutical formulations to improve diabetes management","volume":"13","author":"Maikawa","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.114705_bb0565","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/bit.260400805","article-title":"Mechanism of insulin aggregation and stabilization in agitated aqueous solutions","volume":"40","author":"Sluzky","year":"1992","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2026.114705_bb0570","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/jps.10154","article-title":"Excipient-drug interactions in parenteral formulations","volume":"91","author":"Akers","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0575","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s11095-017-2233-0","article-title":"Rapid-acting and human insulins: hexamer dissociation kinetics upon dilution of the pharmaceutical formulation","volume":"34","author":"Gast","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114705_bb0580","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/jps.24039","article-title":"Effects of phenol and meta-cresol depletion on insulin analog stability at physiological temperature","volume":"103","author":"Teska","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0585","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba6676","article-title":"An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients","volume":"12","author":"Mann","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.114705_bb0590","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/dom.14561","article-title":"Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog\u00ae in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study","volume":"24","author":"Leohr","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb0595","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-019-00834-5","article-title":"Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences","volume":"59","author":"Haahr","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.114705_bb0600","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.114705_bb0605","doi-asserted-by":"crossref","first-page":"31274","DOI":"10.1021\/acsnano.4c10248","article-title":"Engineering supramolecular nanofiber depots from a glucagon-like peptide-1 therapeutic","volume":"18","author":"Chen","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114705_bb0610","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejps.2007.01.003","article-title":"Structural characterization of insulin NPH formulations","volume":"30","author":"Norrman","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0615","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41551-023-01138-7","article-title":"Week-long normoglycaemia in diabetic mice and minipigs via a subcutaneous dose of a glucose-responsive insulin complex","volume":"8","author":"Zhang","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.114705_bb0620","article-title":"Insulin-dendrimer nanocomplex for multi-day glucose-responsive therapy in mice and swine","volume":"36","author":"Xian","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114705_bb0625","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1021\/acsptsci.2c00115","article-title":"Using human serum albumin binding affinities as a proactive strategy to affect the pharmacodynamics and pharmacokinetics of preclinical drug candidates","volume":"5","author":"Fan","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0630","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jmb.2005.07.075","article-title":"Structural basis of the drug-binding specificity of human serum albumin","volume":"353","author":"Ghuman","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0635","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/protein\/12.6.439","article-title":"Crystal structure of human serum albumin at 2.5 A resolution","volume":"12","author":"Sugio","year":"1999","journal-title":"Protein Eng."},{"key":"10.1016\/j.jconrel.2026.114705_bb0640","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1039\/C6SC02267G","article-title":"Circulatory zinc transport is controlled by distinct interdomain sites on mammalian albumins","volume":"7","author":"Handing","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0645","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1006\/jmbi.2000.4158","article-title":"Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin","volume":"303","author":"Bhattacharya","year":"2000","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0650","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/S0021-9258(19)41721-3","article-title":"Long chain fatty acid binding to human plasma albumin","volume":"250","author":"Ashbrook","year":"1975","journal-title":"J. Biol. Chem."},{"issue":"Pt 3","key":"10.1016\/j.jconrel.2026.114705_bb0655","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1042\/bj3120725","article-title":"Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo","volume":"312","author":"Kurtzhals","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.jconrel.2026.114705_bb0660","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0022-2275(20)36723-7","article-title":"Fatty acid binding to plasma albumin","volume":"16","author":"Spector","year":"1975","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2026.114705_bb0665","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1021\/ja210496n","article-title":"A molecular mechanism for modulating plasma Zn speciation by fatty acids","volume":"134","author":"Lu","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114705_bb0670","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jth.12771","article-title":"Plasma free fatty acid levels influence Zn(2+) -dependent histidine-rich glycoprotein-heparin interactions via an allosteric switch on serum albumin","volume":"13","author":"Kassaar","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jconrel.2026.114705_bb0675","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1016\/j.bbagen.2013.05.028","article-title":"Allosteric modulation of zinc speciation by fatty acids","volume":"1830","author":"Barnett","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2026.114705_bb0680","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbalip.2018.09.007","article-title":"Crosstalk between zinc and free fatty acids in plasma","volume":"1864","author":"Coverdale","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.jconrel.2026.114705_bb0685","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","article-title":"A review of the pharmacological properties of insulin degludec and their clinical relevance","volume":"53","author":"Haahr","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.114705_bb0690","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1007\/s13300-020-00915-w","article-title":"Understanding the clinical profile of insulin degludec, the latest basal insulin approved for use in Canada: a narrative review","volume":"11","author":"Woo","year":"2020","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb0695","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13098-015-0037-0","article-title":"Degludec: the new ultra-long insulin analogue","volume":"7","author":"Tambascia","year":"2015","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.jconrel.2026.114705_bb0700","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1023\/B:PHAM.0000036926.54824.37","article-title":"The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin","volume":"21","author":"Havelund","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114705_bb0705","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2165\/11470200-000000000-00000","article-title":"Insulin detemir: a review of its use in the management of diabetes mellitus","volume":"72","author":"Keating","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2026.114705_bb0710","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrd3148","article-title":"Liraglutide","volume":"9","author":"Drucker","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114705_bb0715","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114705_bb0720","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"Biodrugs"},{"key":"10.1016\/j.jconrel.2026.114705_bb0725","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jps.23783","article-title":"Pharmacokinetics of peptide\u2013fc fusion proteins","volume":"103","author":"Benjamin","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0730","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/ajt.15366","article-title":"The neonatal Fc receptor: key to homeostasic control of IgG and IgG-related biopharmaceuticals","volume":"19","author":"Baldwin","year":"2019","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"key":"10.1016\/j.jconrel.2026.114705_bb0735","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-0903-7","article-title":"An intact C-terminal end of albumin is required for its long half-life in humans","volume":"3","author":"Nilsen","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0745","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.114705_bb0750","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/dmrr.1080","article-title":"Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein","volume":"26","author":"Glaesner","year":"2010","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb0755","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","article-title":"Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials","volume":"55","author":"Geiser","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.114705_bb0760","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with Efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114705_bb0765","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2337\/dc22-2395","article-title":"Novel once-weekly basal insulin fc achieved similar glycemic control with a safety profile comparable to insulin degludec in patients with type 1 diabetes","volume":"46","author":"Kazda","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2026.114705_bb0770","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1208\/s12248-023-00873-8","article-title":"Therapeutic fusion proteins","volume":"26","author":"Marsh","year":"2023","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.114705_bb0775","first-page":"126","article-title":"Tanzeum (albiglutide): a once-weekly GLP-1 receptor agonist subcutaneous injection approved for the treatment of patients with type 2 diabetes","volume":"8","author":"Fala","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.jconrel.2026.114705_bb0780","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40262-016-0499-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of albiglutide","volume":"56","author":"Br\u00f8nden","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.114705_bb0785","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.2337\/dc19-2316","article-title":"Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial","volume":"43","author":"Rosenstock","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2026.114705_bb0790","doi-asserted-by":"crossref","first-page":"1700270","DOI":"10.1002\/smtd.201700270","article-title":"Red blood cells for drug delivery","volume":"1","author":"Yan","year":"2017","journal-title":"Small Methods"},{"key":"10.1016\/j.jconrel.2026.114705_bb0795","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.addr.2016.02.007","article-title":"Red blood cells: supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems","volume":"106","author":"Villa","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb0800","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.655393","article-title":"How do red blood cells die?","volume":"12","author":"Thiagarajan","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0805","doi-asserted-by":"crossref","first-page":"1606617","DOI":"10.1002\/adma.201606617","article-title":"Red blood cells for glucose-responsive insulin delivery","volume":"29","author":"Wang","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114705_bb0810","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1007\/s12274-022-4105-0","article-title":"Glucose-responsive erythrocyte-bound nanoparticles for continuously modulated insulin release","volume":"15","author":"Xu","year":"2022","journal-title":"Nano Res."},{"key":"10.1016\/j.jconrel.2026.114705_bb0815","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biot.200900218","article-title":"PEGylation of therapeutic proteins","volume":"5","author":"Jevsevar","year":"2010","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.jconrel.2026.114705_bb0820","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0168-3659(90)90127-F","article-title":"The clinical efficacy of poly(ethylene glycol)-modified proteins","volume":"11","author":"Fuertges","year":"1990","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb0825","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0169-409X(02)00025-X","article-title":"Effects of PEG conjugation on insulin properties","volume":"54","author":"Hinds","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb0830","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/dom.12196","article-title":"PEGylated insulin lispro, (LY2605541) \u2013 a new basal insulin analogue","volume":"16","author":"Caparrotta","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb0835","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2337\/db13-0826","article-title":"Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism","volume":"63","author":"Moore","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb0840","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s13340-016-0255-1","article-title":"Development of new basal insulin peglispro (LY2605541) ends in a disappointing result","volume":"7","author":"Hirose","year":"2016","journal-title":"Diabetol. Int."},{"key":"10.1016\/j.jconrel.2026.114705_bb0845","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13300-016-0214-7","article-title":"How can a good idea fail? Basal insulin peglispro [LY2605541] for the treatment of type 2 diabetes","volume":"8","author":"Mu\u00f1oz-Garach","year":"2017","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb0850","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/cts.12609","article-title":"Impact of insulin tregopil and its permeation enhancer on pharmacokinetics of metformin in healthy volunteers: randomized, open-label, placebo-controlled, crossover study","volume":"12","author":"Khedkar","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0855","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/btpr.487","article-title":"Development of a process to manufacture PEGylated orally bioavailable insulin","volume":"26","author":"Hazra","year":"2010","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.jconrel.2026.114705_bb0860","doi-asserted-by":"crossref","first-page":"1601428","DOI":"10.1002\/adhm.201601428","article-title":"Simple protein modification using zwitterionic polymer to mitigate the bioactivity loss of conjugated insulin","volume":"6","author":"Xie","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.114705_bb0865","article-title":"Long-acting insulin-zwitterionic polymer conjugate mitigates hypoglycemia","volume":"29","author":"Zeng","year":"2023","journal-title":"Chemistry"},{"key":"10.1016\/j.jconrel.2026.114705_bb0870","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41551-020-0555-4","article-title":"A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs","volume":"4","author":"Maikawa","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.114705_bb0875","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1021\/acs.biomac.1c00648","article-title":"Affinity-directed dynamics of host-guest motifs for pharmacokinetic modulation via supramolecular PEGylation","volume":"22","author":"Maikawa","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2026.114705_bb0880","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.apsb.2023.01.007","article-title":"Supramolecular approaches for insulin stabilization without prolonged duration of action","volume":"13","author":"Meudom","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.114705_bb0885","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1021\/acs.biomac.2c01319","article-title":"Supramolecular protein stabilization with zwitterionic polypeptide\u2013cucurbit[7]uril conjugates","volume":"24","author":"Clauss","year":"2023","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2026.114705_bb0890","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/dom.12999","article-title":"Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study","volume":"19","author":"Dassau","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb0895","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126974","article-title":"Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery","volume":"4","author":"Edgerton","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2026.114705_bb0900","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.apsb.2024.02.019","article-title":"Oral peptide therapeutics for diabetes treatment: state-of-the-art and future perspectives","volume":"14","author":"Ding","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.114705_bb0905","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1463-1326.2009.01150.x","article-title":"Oral insulin - a review of current status","volume":"12","author":"Iyer","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb0910","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejps.2008.10.018","article-title":"Absorption kinetics of insulin after subcutaneous administration","volume":"36","author":"S\u00f8eborg","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0915","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s40265-023-01925-1","article-title":"Insulin tregopil: an ultra-fast oral recombinant human insulin analog: preclinical and clinical development in diabetes mellitus","volume":"83","author":"Joshi","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2026.114705_bb0920","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2005.05.022","article-title":"An enteric-coated dry emulsion formulation for oral insulin delivery","volume":"107","author":"Toorisaka","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.125114","article-title":"Oral insulin delivery: barriers, strategies, and formulation approaches: a comprehensive review","volume":"242","author":"Spoorthi Shetty","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2026.114705_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103393","article-title":"Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes","volume":"28","author":"Pang","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.114705_bb0935","article-title":"Oral nanomedicine: challenges and opportunities","volume":"36","author":"Deng","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114705_bb0940","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1007\/s11095-007-9488-9","article-title":"Safe and effective permeation enhancers for oral drug delivery","volume":"25","author":"Whitehead","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114705_bb0945","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207829119","article-title":"The strawberry-derived permeation enhancer pelargonidin enables oral protein delivery","volume":"119","author":"Lamson","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.114705_bb0950","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J","article-title":"Intestinal permeation enhancers","volume":"89","author":"Aungst","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb0955","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0168-3659(94)90072-8","article-title":"Mechanisms of absorption enhancement and tight junction regulation","volume":"29","author":"Hochman","year":"1994","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb0960","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13346-021-01000-w","article-title":"Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery","volume":"12","author":"Lewis","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.114705_bb0965","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.jconrel.2026.114705_bb0970","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0022-3565(25)28988-1","article-title":"The route of absorption of intraperitoneally administered compounds","volume":"178","author":"Lukas","year":"1971","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2230-973X.176456","article-title":"Insulin delivery methods: past, present and future","volume":"6","author":"Shah","year":"2016","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.jconrel.2026.114705_bb0980","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.2337\/db15-0071","article-title":"Insulin delivery into the peripheral circulation: a key contributor to hypoglycemia in type 1 diabetes","volume":"64","author":"Gregory","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb0985","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2337\/db11-1462","article-title":"Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling","volume":"61","author":"Matveyenko","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb0990","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/en.2008-1221","article-title":"Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms","volume":"150","author":"R\u00fcttimann","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2026.114705_bb0995","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4239\/wjd.v3.i8.142","article-title":"Complications of continuous intraperitoneal insulin infusion with an implantable pump","volume":"3","author":"van Dijk","year":"2012","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb1000","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1513\/pats.200409-049TA","article-title":"The lungs as a portal of entry for systemic drug delivery","volume":"1","author":"Patton","year":"2004","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.jconrel.2026.114705_bb1005","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00003088-200443120-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of inhaled insulin","volume":"43","author":"Patton","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.114705_bb1010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0169-409X(98)00074-X","article-title":"Inhaled insulin","volume":"35","author":"Patton","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb1015","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/1932296814555820","article-title":"Afrezza inhaled insulin: the fastest-acting FDA-approved insulin on the market has favorable properties","volume":"8","author":"Klonoff","year":"2014","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114705_bb1020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1177\/193229680800200325","article-title":"The failure of exubera: are we beating a dead horse?","volume":"2","author":"Heinemann","year":"2008","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114705_bb1025","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2337\/diaspect.29.3.180","article-title":"Commentary: why was inhaled insulin a failure in the market?","volume":"29","author":"Oleck","year":"2016","journal-title":"Diabetes Spectr."},{"key":"10.1016\/j.jconrel.2026.114705_bb1030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2015.07.025","article-title":"Future prospect of insulin inhalation for diabetic patients: the case of Afrezza versus Exubera","volume":"215","author":"Al-Tabakha","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb1035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jconrel.2012.01.024","article-title":"Nasal drug delivery - recent developments and future prospects","volume":"161","author":"Illum","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb1040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0169-409X(97)00064-1","article-title":"Optimization of systemic nasal drug delivery with pharmaceutical excipients","volume":"29","author":"Romeo","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb1045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0169-409X(98)00054-4","article-title":"Cyclodextrins in nasal drug delivery","volume":"36","author":"Merkus","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb1050","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/cd19-0013","article-title":"Nasal glucagon: a promising new way to treat severe hypoglycemia","volume":"37","author":"Nguyen","year":"2019","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104421","article-title":"Intranasal transmucosal drug delivery: an alternative approach to the parenteral route for medical emergencies","volume":"83","author":"Vitore","year":"2023","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114705_bb1060","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1089\/dia.2005.7.124","article-title":"Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses","volume":"7","author":"Leary","year":"2005","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb1065","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1177\/193229680800200613","article-title":"Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin\u2122) administered to healthy male volunteers: influence of the nasal cycle","volume":"2","author":"Leary","year":"2008","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114705_bb1070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/193229681100500116","article-title":"Enhanced absorption of Nasulin\u2122, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects","volume":"5","author":"Stote","year":"2011","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114705_bb1075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jconrel.2020.08.013","article-title":"Advancements in the co-formulation of biologic therapeutics","volume":"327","author":"Chauhan","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb1080","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: the advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.114705_bb1085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-015-0106-2","article-title":"Injectable coformulations in diabetology","volume":"6","author":"Kalra","year":"2015","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb1090","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/03007995.2018.1541790","article-title":"Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes","volume":"35","author":"Blonde","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jconrel.2026.114705_bb1095","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/dc19-1922","article-title":"A novel dual-hormone insulin-and-Pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial","volume":"43","author":"Haidar","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2026.114705_bb1100","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1007\/s11095-014-1614-x","article-title":"Investigation of the physico-chemical properties that enable co-formulation of basal insulin degludec with fast-acting insulin aspart","volume":"32","author":"Havelund","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114705_bb1105","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc14-0876","article-title":"Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes","volume":"37","author":"Diamant","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2026.114705_bb1110","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/dc16-1957","article-title":"Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"40","author":"Maiorino","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2026.114705_bb1115","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s12020-023-03543-z","article-title":"IDegLira for type 2 diabetes: a systematic review and meta-analysis","volume":"83","author":"Liu","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.jconrel.2026.114705_bb1120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12020-024-03868-3","article-title":"iGlarLixi for type 2 diabetes: a systematic review and meta-analysis","volume":"86","author":"Liu","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.jconrel.2026.114705_bb1125","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1007\/s12325-023-02567-1","article-title":"The wedding bells sound really good! iGlarLixi fixed-ratio combination in the treatment of type 2 diabetes: a narrative review","volume":"40","author":"Kwiendacz","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb1130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4274\/jcrpe.galenos.2021.2021.0113","article-title":"Efficacy of the novel degludec\/aspart insulin co-formulation in children and adolescents with type 1 diabetes: a real-life experience with one year of IDegAsp therapy in poorly controlled and non-compliant patients","volume":"14","author":"K\u0131rkg\u00f6z","year":"2022","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"10.1016\/j.jconrel.2026.114705_bb1135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s13300-014-0067-x","article-title":"Insulin degludec aspart: the first co-formulation of insulin analogues","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb1140","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ijpharm.2018.06.039","article-title":"Physico-chemical properties of co-formulated fast-acting insulin with pramlintide","volume":"547","author":"da Silva","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114705_bb1145","doi-asserted-by":"crossref","first-page":"2101575","DOI":"10.1002\/advs.202101575","article-title":"Ultra-fast insulin\u2013pramlintide co-formulation for improved glucose management in diabetic rats","volume":"8","author":"Maikawa","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb1150","doi-asserted-by":"crossref","DOI":"10.2337\/db19-150-OR","article-title":"150-OR: BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (PRAM) and human insulin (INS), improves postprandial blood glucose (BG) vs. Both separate injections of PRAM+INS and insulin lispro (LIS) in subjects with T1D","volume":"68","author":"Meiffren","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb1155","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/joim.12837","article-title":"Peptide-based multi-agonists: a new paradigm in metabolic pharmacology","volume":"284","author":"Brandt","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jconrel.2026.114705_bb1160","first-page":"1","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb1165","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb1170","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1004044","article-title":"Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity","volume":"13","author":"Gallwitz","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jconrel.2026.114705_bb1175","doi-asserted-by":"crossref","first-page":"1121387","DOI":"10.3389\/fendo.2023.1121387","article-title":"A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?","volume":"14","author":"Meng","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jconrel.2026.114705_bb1180","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1111\/dom.15140","article-title":"Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: a post hoc assessment of the SURPASS clinical trial programme","volume":"25","author":"Pedersen","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb1185","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.cmet.2024.06.012","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb1190","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114705_bb1195","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41467-022-28683-0","article-title":"Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114705_bb1200","article-title":"Ultra-stable insulin-glucagon fusion protein exploits an endogenous hepatic switch to mitigate hypoglycemic risk","author":"Varas","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.jconrel.2026.114705_bb1205","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801466","article-title":"Biologically inspired and chemically derived methods for glucose-responsive insulin therapy","volume":"8","author":"VandenBerg","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.114705_bb1210","doi-asserted-by":"crossref","first-page":"2300127","DOI":"10.1002\/adtp.202300127","article-title":"Managing diabetes with hydrogel drug delivery","volume":"7","author":"Xiang","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb1215","article-title":"Glucose-responsive insulin and delivery systems: innovation and translation","volume":"32","author":"Wang","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114705_bb1220","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1042\/BST0361457","article-title":"Lectins: past, present and future","volume":"36","author":"Sharon","year":"2008","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jconrel.2026.114705_bb1225","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1021\/ac303689j","article-title":"Optimization of a Concanavalin A-based glucose sensor using fluorescence anisotropy","volume":"85","author":"Cummins","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb1230","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1126\/science.505005","article-title":"A glucose-controlled insulin-delivery system: semisynthetic insulin bound to lectin","volume":"206","author":"Brownlee","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.114705_bb1235","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2337\/diab.32.6.499","article-title":"Glycosylated insulin complexed to Concanavalin A. Biochemical basis for a closed-loop insulin delivery system","volume":"32","author":"Brownlee","year":"1983","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb1240","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97476","article-title":"A glucose-responsive insulin therapy protects animals against hypoglycemia","volume":"3","author":"Yang","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2026.114705_bb1245","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db17-0577","article-title":"Engineering glucose responsiveness into insulin","volume":"67","author":"Kaarsholm","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb1250","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/cpt.1215","article-title":"Clinical evaluation of MK-2640: an insulin analog with glucose-responsive properties","volume":"105","author":"Krug","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2026.114705_bb1255","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202100118","article-title":"Insulin delivery using dynamic covalent boronic acid\/ester-controlled release","volume":"4","author":"Banach","year":"2021","journal-title":"Adv. Therapeut."},{"key":"10.1016\/j.jconrel.2026.114705_bb1260","doi-asserted-by":"crossref","first-page":"11205","DOI":"10.1016\/j.tet.2004.08.051","article-title":"The relationship among pKa, pH, and binding constants in the interactions between boronic acids and diols\u2014it is not as simple as it appears","volume":"60","author":"Yan","year":"2004","journal-title":"Tetrahedron"},{"key":"10.1016\/j.jconrel.2026.114705_bb1265","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1073\/pnas.1424684112","article-title":"Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates","volume":"112","author":"Chou","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.114705_bb1270","article-title":"Insertion of a synthetic switch into insulin provides metabolite-dependent regulation of hormone-receptor activation","volume":"118","author":"Chen","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.114705_bb1275","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/adma.201502902","article-title":"Injectable self-healing glucose-responsive hydrogels with pH-regulated mechanical properties","volume":"28","author":"Yesilyurt","year":"2016","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114705_bb1280","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jconrel.2022.06.016","article-title":"Diboronate crosslinking: introducing glucose specificity in glucose-responsive dynamic-covalent networks","volume":"348","author":"Xiang","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb1285","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1021\/acs.biomac.2c00878","article-title":"Polymeric microneedle arrays with glucose-sensing dynamic-covalent bonding for insulin delivery","volume":"23","author":"Ye","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2026.114705_bb1290","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1039\/D4ME00106K","article-title":"Enhanced glucose-responsivity of PBA\u2013diol hydrogel networks by reducing crosslink affinity","volume":"10","author":"Xian","year":"2025","journal-title":"Mol. Syst. Des. Eng."},{"key":"10.1016\/j.jconrel.2026.114705_bb1295","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1021\/jacs.3c13139","article-title":"Glucose-driven droplet formation in complexes of a supramolecular peptide and therapeutic protein","volume":"146","author":"Yu","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114705_bb1300","doi-asserted-by":"crossref","DOI":"10.1002\/jbm.a.37854","article-title":"Supramolecular peptide depots for glucose-responsive glucagon delivery","volume":"113","author":"Chen","year":"2025","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.jconrel.2026.114705_bb1305","doi-asserted-by":"crossref","first-page":"2311498","DOI":"10.1002\/adma.202311498","article-title":"Glucose-triggered gelation of supramolecular peptide nanocoils with glucose-binding motifs","volume":"36","author":"Yu","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114705_bb1310","doi-asserted-by":"crossref","DOI":"10.1002\/syst.202200050","article-title":"Molecular engineering of carbohydrate recognition","volume":"5","author":"Sun","year":"2023","journal-title":"ChemSystemsChem"},{"key":"10.1016\/j.jconrel.2026.114705_bb1315","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1039\/C9CS00391F","article-title":"Biomimetic carbohydrate recognition","volume":"49","author":"Davis","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2026.114705_bb1320","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41557-018-0155-z","article-title":"A biomimetic receptor for glucose","volume":"11","author":"Tromans","year":"2018","journal-title":"Nat. Chem."},{"key":"10.1016\/j.jconrel.2026.114705_bb1325","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/s41586-024-08042-3","article-title":"Glucose-sensitive insulin with attenuation of hypoglycaemia","volume":"634","author":"Hoeg-Jensen","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.114705_bb1330","doi-asserted-by":"crossref","first-page":"19588","DOI":"10.1039\/D4SC06190J","article-title":"From small changes to big gains: pyridinium-based tetralactam macrocycle for enhanced sugar recognition in water","volume":"15","author":"Zhai","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb1335","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.biotechadv.2009.04.003","article-title":"Glucose oxidase \u2013 an overview","volume":"27","author":"Bankar","year":"2009","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2026.114705_bb1340","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1295\/polymj.16.625","article-title":"Glucose induced permeation control of insulin through a complex membrane consisting of immobilized glucose oxidase and a poly(amine)","author":"Ishihara","year":"1984","journal-title":"Polym. J."},{"key":"10.1016\/j.jconrel.2026.114705_bb1345","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0168-3659(85)90041-0","article-title":"Glucose sensitive membranes for controlled delivery of insulin: insulin transport studies","author":"Albin","year":"1985","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb1350","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0168-3659(00)00195-4","article-title":"Glucose-sensitivity of glucose oxidase-containing cationic copolymer hydrogels having poly(ethylene glycol) grafts","volume":"67","author":"Podual","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb1355","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0168-3659(89)90063-1","article-title":"An insulin-releasing system that is responsive to glucose","author":"Ito","year":"1989","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb1360","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.1021\/ma970117g","article-title":"Dynamic behavior of glucose-responsive poly(methacrylic acid-g-ethylene glycol) hydrogels","author":"Hassan","year":"1997","journal-title":"Macromolecules"},{"key":"10.1016\/j.jconrel.2026.114705_bb1365","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2004.02.026","article-title":"Control of pore size and permeability of a glucose-responsive gating membrane for insulin delivery","volume":"97","author":"Chu","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb1370","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(02)00409-1","article-title":"A sulfonamide based glucose-responsive hydrogel with covalently immobilized glucose oxidase and catalase","volume":"86","author":"Kang","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114705_bb1375","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1021\/nn400630x","article-title":"Injectable nano-network for glucose-mediated insulin delivery","volume":"7","author":"Gu","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114705_bb1380","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1021\/nn401617u","article-title":"Glucose-responsive microgels integrated with enzyme nanocapsules for closed-loop insulin delivery","volume":"7","author":"Gu","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114705_bb1385","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/marc.201200411","article-title":"Glucose-regulated insulin release from acid-disintegrable microgels covalently immobilized with glucose oxidase and catalase","volume":"33","author":"Wu","year":"2012","journal-title":"Macromol. Rapid Commun."},{"key":"10.1016\/j.jconrel.2026.114705_bb1390","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1021\/bm500364a","article-title":"Bio-inspired synthetic nanovesicles for glucose-responsive release of insulin","volume":"15","author":"Tai","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2026.114705_bb1395","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.biomaterials.2010.11.002","article-title":"Controlled insulin release from glucose-sensitive self-assembled multilayer films based on 21-arm star polymer","volume":"32","author":"Chen","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.114705_bb1400","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1039\/C6CC02202B","article-title":"Glucose-sensitive polymer nanoparticles for self-regulated drug delivery","volume":"52","author":"Zhao","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2026.114705_bb1405","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1021\/acsnano.9b06395","article-title":"Glucose-responsive nanoparticles for rapid and extended self-regulated insulin delivery","volume":"14","author":"Volpatti","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114705_bb1410","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1016\/S0142-9612(03)00441-1","article-title":"Degradation of phospholipid polymer hydrogel by hydrogen peroxide aiming at insulin release device","volume":"24","author":"Uchiyama","year":"2003","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.114705_bb1415","doi-asserted-by":"crossref","first-page":"8260","DOI":"10.1073\/pnas.1505405112","article-title":"Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery","volume":"112","author":"Yu","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.114705_bb1420","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1021\/jacs.1c04570","article-title":"Glucose-fueled peptide assembly: glucagon delivery via enzymatic actuation","volume":"143","author":"Yu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114705_bb1425","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","article-title":"Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics","volume":"55","author":"Jacobsen","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.114705_bb1430","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/dom.13186","article-title":"Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment","volume":"20","author":"Jensen","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb1435","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/bcp.13135","article-title":"Population pharmacokinetics of exenatide","volume":"83","author":"Cirincione","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114705_bb1440","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1310\/hpj5201-65","article-title":"Lixisenatide","volume":"52","author":"Baker","year":"2017","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.jconrel.2026.114705_bb1445","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/pedi.13343","article-title":"A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes","volume":"23","author":"Barrientos-P\u00e9rez","year":"2022","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.jconrel.2026.114705_bb1450","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1463-1326.2008.00992.x","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects","volume":"11","author":"Bush","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb1455","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/dom.14635","article-title":"Pharmacokinetic and pharmacodynamic equivalence of Biocon\u2019s biosimilar insulin-R with the US-licensed Humulin\u00ae R formulation in healthy subjects: results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study","volume":"24","author":"Plum-M\u00f6rschel","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb1460","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1001\/jama.289.17.2254","article-title":"Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review","volume":"289","author":"DeWitt","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2026.114705_bb1465","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.2147\/PPA.S92123","article-title":"Insulin glargine 300 U\/mL in the management of diabetes: clinical utility and patient perspectives","volume":"10","author":"de Galan","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.jconrel.2026.114705_bb1470","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2337\/diacare.23.5.644","article-title":"Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo","volume":"23","author":"Heinemann","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2026.114705_bb1475","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1463-1326.2005.00487.x","article-title":"Insulin detemir: a new basal insulin analogue","volume":"8","author":"Soran","year":"2006","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114705_bb1480","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40262-021-01084-0","article-title":"Comparison of pharmacokinetics and pharmacodynamics of inhaled technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus","volume":"61","author":"Grant","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.114705_bb1485","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40261-017-0499-y","article-title":"Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions","volume":"37","author":"H\u00f6velmann","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jconrel.2026.114705_bb1490","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00003088-200847010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of insulin glulisine","volume":"47","author":"Becker","year":"2008","journal-title":"Clin. Pharmacokinet."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:36:34Z","timestamp":1787128594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926001070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":298,"alternative-id":["S0168365926001070"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114705","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular engineering of designer diabetes therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114705"}}